Adam Rosenberg lifts the curtain on what biotech venture partners and entrepreneurs-in-residence really do.

We’re glad you’re here. Read more about the genesis of RApport and our mission and goals.

The difference between investing in space exploration and investing in the biotech industry is about who bears the cost: society as a whole or people as individuals.

ICER released a report concluding that Vertex’s groundbreaking triple-combination cystic fibrosis (CF) drug, Trikafta, is too expensive for the value it provides to patients. But is it?

Whatever therapy or intervention solves a previously unmet need is inherently novel. So any treatments for COVID-19 that turn out to work will be "novel" in every way that matters.